Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Efficacy of RTS,S malaria vaccine declines over seven years

Research

Results from a long-term phase II study of the malaria vaccine RTS,S show that its efficacy falls over time, and that this decline is fastest in children living in areas with higher than average rates of malaria.

© Kateryna Kon - Shutterstock

Image courtesy of Shutterstock

The findings, published in the New England Journal of Medicine, suggest that the benefits of the vaccine are likely to vary across different populations and highlight the need for more research to determine the most effective way of using RTS,S, which last year became the first ever malaria vaccine to receive a green light from the European Medicines Agency.

Read more

Similar stories

Drug could help diabetic hearts recover after heart attack - Oxford research

Researchers at the University of Oxford have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks.

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.

Increased infectiousness of coronavirus variants explained

Researchers from the Universities of Oxford and Dundee have made a discovery that helps explain why variations in the virus causes COVID-19 to spread so rapidly.